Vanda Pharmaceuticals (VNDA) Receives FDA Approval for Iloperidone

November 27, 2007 8:44 AM EST Send to a Friend
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. FDA has officially accepted its New Drug Application for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia. By accepting the NDA, the FDA confirms that the application is sufficiently complete for regulatory review.

Vanda Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of clinical-stage drug candidates for various central nervous system disorders.

You May Also Be Interested In





Related Categories

FDA

Add Your Comment